ProfileGDS5678 / 1437198_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 62% 56% 66% 62% 54% 59% 60% 65% 61% 64% 67% 60% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.735962
GSM967853U87-EV human glioblastoma xenograft - Control 23.732662
GSM967854U87-EV human glioblastoma xenograft - Control 33.4114456
GSM967855U87-EV human glioblastoma xenograft - Control 43.9593566
GSM967856U87-EV human glioblastoma xenograft - Control 53.6711162
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4458854
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6245459
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5668460
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9459465
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6335961
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8130664
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0840767
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6060360
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5890260